Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

Shares of several obesity-focused stocks dropped on Wednesday after Swiss pharma giant Roche (RHHBY) announced positive top-line results from an early-stage study on its experimental obesity drug CT-996. Both these incretin-based candidates were added to Roche's pipeline from the acquisition of privately owned Carmot Therapeutics for $2.7 billion in January. The acquisition also added CT-868, a once-daily, subcutaneously injected drug, which is being developed in a mid-stage study as a first-in-class treatm ...